Insomnia: Zolpidem extended-release for the treatment of sleep induction and sleep maintenance symptoms

MedGenMed Medscape General Medicine

Volumn 9, Issue 1, 2007, Pages

  Doghramji, Paul P ^a  

^a Collegeville Family Practice ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZALEPLON; ZOLPIDEM TARTRATE; PYRIDINE DERIVATIVE; ZOLPIDEM;

CLINICAL TRIAL; COGNITION; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; HUMAN; INSOMNIA; POLYSOMNOGRAPHY; PSYCHOMOTOR PERFORMANCE; REVIEW; SLEEP INDUCTION; SUSTAINED RELEASE PREPARATION; WAKEFULNESS; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SLEEP; SLEEP STAGE;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES;

EID: 33846519925     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep. 2005;28:1049-1057. Abstract
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2002.
3. Elwood P, Hack M, Pickering J, Hughes J, Gallacher J. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health. 2006;60:69-73. Abstract
4. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411-418. Abstract
5. Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165:863-867. Abstract
6. Idzikowski C. Impact of insomnia on health-related quality of life. Pharmacoeconomics. 1996;10(suppl1):15-24.
7. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18:246-251. Abstract
8. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc. 2001;49:1185-1189. Abstract
9. Riemann D, Berger M, Voderholzer U. Sleep and depression - results from psychobiological studies: an overview. Biol Psychol. 2001;57:67-103. Abstract
10. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052-1060. Abstract
11. Stepanski EJ, Rybarczyk B. Emerging research on the treatment and etiology of secondary or comorbid insomnia. Sleep Med Rev. 2006;10:7-18. Abstract
12. Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep. 1999;22 (suppl2):S359-S365.
13. Winkelman JW. A primary care approach to insomnia management. Medscape. Copyright 2005. Available at: http://www.medscape.com/viewprogram/ 3807_index Accessed January 3, 2007.
14. Leger D, Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. 2005;21:1785-1792. Abstract
15. Hohagen F, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17:551-554. Abstract
16. Buysse DJ, Finn L, Young T. Onset, remission, persistence, and consistency of insomnia symptoms over 10 years: longitudinal results from the Wisconsin Sleep Cohort Study (WSCS). Sleep. 2004;27:A268. Abstract 602.
17. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199. Abstract
18. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991, National Sleep Foundation Survey. II. Sleep. 1999;22(suppl2):S354-S358.
19. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18:49-56. Abstract
20. Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C, Krupka E. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20:397-403. Abstract
21. Blin O, Micallef-Roll J, Audebert C, Legangneux E. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol. 2006;26:284-289. Abstract
22. Hindmarch I. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol. In press.
23. Hindmarch I, Stanley N, Legangneux E, Emegbo S. Zolpidem modified-release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard zolpidem 10 mg. Pharmacotherapy. 2005;25:1504. Abstract 321.
24. Moen MD, Plosker GL. Zolpidem extended-release. CNS Drugs. 2006;20:419-426. Abstract
25. Hindmarch I, Stanley N, Legangneux E, Emegbo S. Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours postdose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening. Sleep. 2005;28(suppl):A245. Abstract 0731.
26. Roehrs T, Soubrane C, Walsh J, Roth T. Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia. Sleep. 2005;28(suppl):A244. Abstract 0725.
27. Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7:397-406. Abstract
28. Erman M, Krystal A, Zammit G, Soubrane C, Roth T. Zolpidem extended-release 12.5 mg, taken for 24 weeks "as needed" up to 7 nights/week, improves subjective measures of therapeutic global impression, sleep onset, and sleep maintenance in patients with chronic insomnia. Int J Neuropsychopharmacol. 2006;9 (suppl1):S256. Abstract P03.106.